AcquiSci Inc. is developing d-OSAB™, its medical device-based technology that will widen the present window of treatment for ischemic stroke to 12 to 18 hours from occurrence, offering the potential to treat a vast majority of the 94% of stroke victims that cannot currently be treated.
The company's technology is based upon evoking a naturally occurring anti-inflammatory process in the body by inducing white blood cells through a transfusion-like process, to undergo what is known as apoptosis (programmed cell death). The treatment is simple to use and can be administered in 20 minutes by a nurse or anyone that is licensed to draw blood.
The following video provides a brief overview of AcquiSci's breakthrough technology:
AcquiSci's process has therapeutic applications in other inflammatory diseases such as Chronic Heart Failure (CHF), and in the sterilization of biofluids to prevent prion infectious contamination for products emanating from animals; addressing Mad Cow and Creutzfeldt-Jakob diseases.
AcquiSci welcomes the opportunity to work with universities and not-for profit organizations but the Company will pay no more than 35% overhead.